Evidence map›Paper›PMID 31842810›Full record

ArticleBMC cancer2019

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.

Eugenio Zoni, Martina Minoli, Cédric Bovet, Anne Wehrhan, Salvatore Piscuoglio, Charlotte K Y Ng, Peter C Gray, Martin Spahn, George N Thalmann, Marianna Kruithof-de Julio

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Spatial multi-omics reveals the potential involvement of SPP1Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  5. Article
  6. Acylcarnitine Profiling in Meningiomas with Different NF2 Mutation Statuses.International journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.Frontiers in cellular and infection microbiology · 2021
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Eugenio ZoniDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Martina MinoliDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Cédric BovetUniversity Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Anne WehrhanUniversity Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Salvatore PiscuoglioInstitute of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Charlotte K Y NgVisceral Surgery Research Laboratory, Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland.
Peter C GrayScienceMedia Inc, 8910 University Center Ln Suite 400, San Diego, CA, 92122, USA.
Martin SpahnZentrum für Urologie Zürich und Prostatakarzinomzentrum Hirslanden ZürichKlinik Hirslanden, Zürich, Switzerland.
George N ThalmannDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Marianna Kruithof-de JulioDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland. marianna.kruithofdejulio@dbmr.unibe.ch.ORCID http://orcid.org/0000-0002-6085-7706
University of Bern · CHBern University of Applied Sciences · CHKlinik Hirslanden · CHScienceMedia (United States) · USUniversity of Basel · CH

Funding

Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland NASchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 31003A_169352Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PZ00P3_168165
6 · The paper itself

Abstract

backgroundLittle is known about the relationship between the metabolite profile of plasma from pre-operative prostate cancer (PCa) patients and the risk of PCa progression. In this study we investigated the association between pre-operative plasma metabolites and risk of biochemical-, local- and metastatic-recurrence, with the aim of improving patient stratification.

methodsWe conducted a case-control study within a cohort of PCa patients recruited between 1996 and 2015. The age-matched primary cases (n = 33) were stratified in low risk, high risk without progression and high risk with progression as defined by the National Comprehensive Cancer Network. These samples were compared to metastatic (n = 9) and healthy controls (n = 10). The pre-operative plasma from primary cases and the plasma from metastatic patients and controls were assessed with untargeted metabolomics by LC-MS. The association between risk of progression and metabolite abundance was calculated using multivariate Cox proportional-hazard regression and the relationship between metabolites and outcome was calculated using median cut-off normalized values of metabolite abundance by Log-Rank test using the Kaplan Meier method.

resultsMedium-chain acylcarnitines (C6-C12) were positively associated with the risk of PSA progression (p = 0.036, median cut-off) while long-chain acylcarnitines (C14-C16) were inversely associated with local (p = 0.034) and bone progression (p = 0.0033). In primary cases, medium-chain acylcarnitines were positively associated with suberic acid, which also correlated with the risk of PSA progression (p = 0.032, Log-Rank test). In the metastatic samples, this effect was consistent for hexanoylcarnitine, L.octanoylcarnitine and decanoylcarnitine. Medium-chain acylcarnitines and suberic acid displayed the same inverse association with tryptophan, while indoleacetic acid, a breakdown product of tryptophan metabolism was strongly associated with PSA (p = 0.0081, Log-Rank test) and lymph node progression (p = 0.025, Log-Rank test). These data were consistent with the increased expression of indoleamine 2,3 dioxygenase (IDO1) in metastatic versus primary samples (p = 0.014). Finally, functional experiments revealed a synergistic effect of long chain fatty acids in combination with dihydrotestosterone administration on the transcription of androgen responsive genes.

conclusionsThis study strengthens the emerging link between fatty acid metabolism and PCa progression and suggests that measuring levels of medium- and long-chain acylcarnitines in pre-operative patient plasma may provide a basis for improving patient stratification.

Indexed as

MetabolomicsAgedCarnitineCase-Control StudiesChromatography, LiquidDisease ProgressionFatty AcidsHumansMaleMass SpectrometryMiddle AgedPrognosisProstatic NeoplasmsWhite PeopleacylcarnitineCarnitinedecanoylcarnitineFatty AcidshexanoylcarnitineoctanoylcarnitineAcylcarnitinesDisease progressionFatty acid metabolismMetabolomicsProstate cancer

Identifiers

PMID31842810
PMCPMC6916032
OpenAlexW2996697499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.